EB-203
Phase 2Small molecule
EB-203 is one of 39 small molecule programs targeting Age-Related Macular Degeneration. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
237 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronPhase 3
Lucentis
RochePhase 3
Vabysmo
RochePhase 3
Beovu
NovartisPhase 3
Macugen
PfizerPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Retaane
AAlcon Research
Phase 3
Forzinity
SStealth BioTherapeutics Inc.
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EB-203. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEyebioKorea, Inc.